Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
about
TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma membrane recruitment triggered by the B-cell antigen receptorThe PI3K-PDK1 connection: more than just a road to PKBThe B lymphocyte adaptor molecule of 32 kD (Bam32) regulates B cell antigen receptor signaling and cell survivalA novel B lymphocyte-associated adaptor protein, Bam32, regulates antigen receptor signaling downstream of phosphatidylinositol 3-kinaseSyk: a new player in the field of breast cancerManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsRegulation of Akt/PKB activation by tyrosine phosphorylationB-cell receptor signalling and its crosstalk with other pathways in normal and malignant cellsPharmacological comparison of LTB(4)-induced NADPH oxidase activation in adherent and non-adherent guinea-pig eosinophilsTargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaA phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.The LMP2A ITAM is essential for providing B cells with development and survival signals in vivoLatent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells.Akt1 and Akt2 promote peripheral B-cell maturation and survival.Src family kinases mediate receptor-stimulated, phosphoinositide 3-kinase-dependent, tyrosine phosphorylation of dual adaptor for phosphotyrosine and 3-phosphoinositides-1 in endothelial and B cell lines.The adaptor protein Bam32 regulates Rac1 activation and actin remodeling through a phosphorylation-dependent mechanism.Subversion of B lymphocyte signaling by infectious agents.The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyreneBAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism.Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.Akt-dependent cytokine production in mast cells.BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway.The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.Cross-linking of FcepsilonRI causes Ca2+ mobilization via a sphingosine kinase pathway in a clathrin-dependent manner.Mediation of transitional B cell maturation in the absence of functional Bruton's tyrosine kinase.The role of the tec kinase Bruton's tyrosine kinase (Btk) in leukocyte recruitment.Translational hematology.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.Arrhythmic complications of tyrosine kinase inhibitors.State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.
P2860
Q24300968-0E244587-F15C-4D06-8410-CDA6D605F5E8Q24531972-6632EED5-8826-4282-BF5D-03128485BFB8Q24670427-0447DEFD-E6B5-4EC2-9ACA-D870F77F922BQ24676484-87793102-D290-4BF9-8301-877B66EE5EC7Q24801099-C0B2AAD7-6559-4436-817A-2CBA789934C5Q28081162-EA2E31D5-D157-456C-8C97-93F5CE2F0A20Q28205568-107E6496-2979-40D9-A477-EFA63E2A7363Q28245018-4BAC363F-C34D-4BBD-87CF-A6BB2E81D9C9Q28362069-2E505E87-9BAA-42BC-A30E-98AAEC7D2DCBQ29620690-615C42EF-CC47-4C75-BEB0-6BB878055366Q33206929-61F5F7B0-6ECC-40EA-9BF1-14792E93A9B7Q33604616-9A36EB08-7CE7-42AF-9F29-4A299FB3052CQ33787396-9CA48B03-4A12-42E5-BAC4-CB22772E01C1Q33794555-BF12697D-A11B-4715-A4A6-9169622177C7Q33871508-C9BC65DC-902A-4E22-AA9B-54C983B959E5Q34088298-60C5AFFF-6AC9-4311-9AFF-D12D98153E1FQ34332633-D6CE39C1-6B72-434C-A058-929DDB295699Q35078625-20D1F421-7D7A-46BB-8F04-4E8DE051C578Q35583403-642BA5DB-7615-436E-BCC1-2E6132094ADCQ35775881-34E03F3C-C24A-4239-AD2C-5D7B9D5B1F3DQ35784522-6B268C11-9F26-49B7-AA4E-0302F738762FQ35953518-D5CAB9D1-22F5-412E-B631-A289765E6806Q36020691-6C0FA82A-39BD-4996-ACB1-1AE546C9DBB2Q36228028-0864C4E2-81A2-4712-81FF-43735537F960Q36368492-AF67F037-9D00-4406-A754-3850988B9C59Q36368818-03CE2EB4-AC93-4B5A-889F-0BEC48A96993Q36403102-F487384E-325B-460B-A53F-EE24DF89764CQ37084564-8E419805-06A8-4046-A4DE-E926CA37BD51Q37145587-AEA4628C-93D1-4346-8C5B-4FE457152F33Q37737830-24818276-28D8-40E8-A400-6CAFB89AF725Q37997074-D8967602-5C71-454F-8AEE-8D06D6571CE0Q38247744-E5C49E14-0AF1-471D-83B6-3A6C88A9087BQ38719429-D306B0BA-90E2-4922-A266-181BE82513F2Q38815946-0629E164-0169-4672-A0A5-A863A5C0E3D4Q38978097-8F1F5F88-5142-4933-83B2-69B895243685Q39085428-9D042C11-1385-46E7-AFAA-92C7F4099CC9Q39200835-217E0BF9-554C-471B-9974-21E0D318E067Q39325783-429A2933-0F99-4BE0-90D5-AC60073024DFQ40594564-E907A357-6FC2-4D5E-9557-3F0DA8385F70Q40736037-15F0450D-DC66-4499-863E-D82DD74DEAD0
P2860
Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Syk and Bruton's tyrosine kina ...... activation of the kinase Akt.
@en
type
label
Syk and Bruton's tyrosine kina ...... activation of the kinase Akt.
@en
prefLabel
Syk and Bruton's tyrosine kina ...... activation of the kinase Akt.
@en
P2093
P2860
P356
P1476
Syk and Bruton's tyrosine kina ...... activation of the kinase Akt.
@en
P2093
P2860
P304
30644-30650
P356
10.1074/JBC.274.43.30644
P407
P577
1999-10-01T00:00:00Z